Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675
eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3
oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a
26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.